Core Viewpoint - Company Kojis Pharmaceuticals (02171) announced a share buyback plan, intending to repurchase 1.01 million shares for a total cost of HKD 14.762 million, scheduled for December 16, 2025 [1] Group 1 - The total amount allocated for the share buyback is HKD 14.762 million [1] - The number of shares to be repurchased is 1.01 million [1] - The buyback is set to occur on December 16, 2025 [1]

智通财经APP讯，科济药业-B(02171)发布公告，于2025年12月16日斥资1476.2万港元回购101万股。 ...

格隆汇12月16日丨科济药业-B(02171.HK)公告，12月16日耗资1476.2万港元回购101万股。 ...

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 第 1 頁 共 7 頁 v 1.3.0 | 1). | 股份回購待註銷但尚未註銷 | | 250,000 | 0.043 % | HKD | 17.08 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年10月21日 | | | | | | 2). | 股份回購待註銷但尚未註銷 | | 205,000 | 0.035 % | HKD | 16.58 | | | 變動日期 | 2025年10月23日 | | | | | 第 2 頁 共 7 頁 v 1.3.0 FF305 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年12月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章 ...

Core Insights - The article discusses the stock buyback activities of various companies, highlighting the total amounts and quantities repurchased, with Tencent Holdings leading the buyback efforts [1][2]. Group 1: Buyback Overview - Tencent Holdings (00700) repurchased 1.051 million shares for a total of 636 million, representing 0.995% of its total share capital [2]. - Xiaomi Group (01810) repurchased 7.2 million shares for 302 million, accounting for 0.430% of its total share capital [2]. - China COSCO Shipping Holdings (01919) repurchased 2.95 million shares for 40.016 million, which is 3.089% of its total share capital [2]. Group 2: Notable Buybacks - Kuaishou Technology (01024) repurchased 462,000 shares for 29.9304 million, representing 0.191% of its total share capital [2]. - Kingsoft Corporation (03888) repurchased 702,800 shares for 19.9994 million, which is 0.580% of its total share capital [2]. - Country Garden Services (06098) repurchased 3 million shares for 18.9615 million, accounting for 1.284% of its total share capital [2]. Group 3: Other Companies - Coolpad Group (02369) repurchased 3.16 million shares for 4.1717 million, representing 7.986% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 764,000 shares for 3.306 million, which is 0.190% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 200,000 shares for 2.9675 million, accounting for 0.762% of its total share capital [2].

Core Insights - The release of the new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory marks a significant shift in China's healthcare system towards a dual-driven model of "basic medical insurance + commercial health insurance" [1][2] Group 1: Policy Changes - The new directories will be implemented on January 1, 2026, and represent a milestone in establishing a multi-tiered medical insurance system in China [2] - The Commercial Health Insurance Innovative Drug Directory provides a high-quality "drug pool" for insurance companies, reducing the barriers for product development and information asymmetry [2][3] - The basic medical insurance directory has added 114 new drugs, achieving a negotiation success rate of 88.19%, the highest in seven years, enhancing drug coverage in critical areas [3][4] Group 2: Drug Inclusion and Coverage - The first Commercial Health Insurance Innovative Drug Directory includes 19 drugs, focusing on high-value innovative treatments that exceed basic insurance coverage, such as CAR-T therapies and Alzheimer's drugs [4][5] - Five CAR-T therapies have been included in the directory, representing over half of the currently available products in China, with prices exceeding 1 million yuan for most [5][6] - The directory also includes treatments for rare diseases, demonstrating a commitment to vulnerable populations [6] Group 3: Market Dynamics - The dual-directory system is designed to address the structural challenges of high-value innovative drugs, allowing commercial insurance to cover these costs before they are potentially included in basic insurance [7][8] - The introduction of commercial insurance funding is expected to enhance the clinical drug level and overall R&D return rates for leading innovative pharmaceutical companies [6][11] Group 4: Consumer Impact - The new payment structure allows patients to access innovative therapies without facing the dilemma of full out-of-pocket costs, as commercial insurance will provide support [8][9] - The expansion of special drug lists in commercial insurance products is becoming a trend, with many regions updating their offerings to include high-value cancer and rare disease medications [9][10] - However, challenges remain in ensuring that hospitals stock these high-cost drugs and that the claims process is efficient and transparent [10]

Group 1 - The company Kintor Pharmaceutical Co., Ltd. (stock code: 02171) announced a share buyback plan [1] - The company will spend HKD 7.9076 million to repurchase 522,000 shares [1]

智通财经APP讯，科济药业-B(02171)发布公告，于2025年12月15日斥资790.76万港元回购52.2万股。 ...

格隆汇12月15日丨科济药业-B(02171.HK)公告，12月15日耗资790.8万港元回购52.2万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年12月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫 ...